Notice Pursuant To the National Cooperative Research and Production Act of 1993-Medical CBRN Defense Consortium, 74386 [2020-25693]

Download as PDF 74386 Federal Register / Vol. 85, No. 225 / Friday, November 20, 2020 / Notices Research Corporation, Huntsville, AL; Efiia Consulting, LLC, Falls Church, VA; Eirene Technologies, Inc., La Mesa, CA; Enviornics USA, Inc., Round Rock, TX; GeneInfoSec, Inc., Boulder, CO; GenScript USA, Inc., Piscataway, NJ; PeopleTec, Inc., Huntsville, AL; Raytheon Company, Tuscon, AZ; SaintGobain Crystals, Hiram, OH; and Women Veterans Contracting, Inc., San Diego, CA have been added as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and CWMD intends to file additional written notifications disclosing all changes in membership. On January 31, 2018, CWMD filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on March 12, 2018 (83 FR 10750). The last notification was filed with the Department on August 17, 2020. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on August 28, 2020 (85 FR 53400). Suzanne Morris, Chief, Premerger and Division Statistics, Antitrust Division. Kern Technology Group. LLC, Virginia Beach, VA; ManTech Advanced Systems International (ManTech), Herndon, VA; McCormick Stevenson Corporation, Clearwater, FL; Moire Inc., Issaquah, WA; NKT Photonics Inc., Boston, MA; Pure Watercraft, Inc., Seattle, WA; SEARCH, Inc., Orlando, FL; University of Delaware College of Earth, Ocean and Environment, Newark, DE; VivSoft Technologies, LLC, Brambleton, VA; and White River Technologies, Inc., Newton, MA have been added as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and UTIC intends to file additional written notifications disclosing all changes in membership. On October 9, 2018, UTIC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on November 2, 2018 (83 FR 55203). The last notification was filed with the Department on July 13, 2020. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on July 31, 2020 (85 FR 46176). [FR Doc. 2020–25695 Filed 11–19–20; 8:45 am] Suzanne Morris, Chief, Premerger and Division Statistics, Antitrust Division. BILLING CODE P [FR Doc. 2020–25696 Filed 11–19–20; 8:45 am] BILLING CODE 4410–11–P DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Antitrust Division khammond on DSKJM1Z7X2PROD with NOTICES Notice Pursuant to The National Cooperative Research and Production Act of 1993—Undersea Technology Innovation Consortium Notice is hereby given that, on November 9, 2020, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Undersea Technology Innovation Consortium (‘‘UTIC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, DE Technologies, King of Prussia, PA; EFW Inc., An Elbit Systems of America Company, Fort Worth, TX; Ensign Bickerford Aerospace & Defense (EBAD), Simsbury, CT; GenOne Technologies, LLC, Cambridge, MA; IT Mentor Group, Inc., San Diego, CA; VerDate Sep<11>2014 17:08 Nov 19, 2020 Jkt 253001 Antitrust Division Notice Pursuant To the National Cooperative Research and Production Act of 1993—Medical CBRN Defense Consortium Notice is hereby given that, on October 20, 2020, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Medical CBRN Defense Consortium (‘‘MCDC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Aardvark Medical, Inc.; Ross, CA; Acer Therapeutics, Inc.; Newton, MA; Aegis BioDefense, Inc.; San Carlos, CA; Albany Molecular Research Inc. (AMRI); Albany, NY; Arcturus Therapeutics; San Diego, CA; PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 ARMSTEL, Inc.; Plano, TX; C2Sense, Inc.; Watertown, MA; Captura Biopharma, Inc.; Little Rock, AR; Concord Medical Technology Corporation; Grand Forks, ND; Efiia Consulting, LLC; Falls Church, VA; Equillium, Inc.; La Jolla, CA; EUSA Pharma (US), LLC; Burlington, MA; EWI; Columbus, OH; GenScript USA, Inc.; Piscataway, NJ; Kleo Pharmaceuticals; New Haven, CT; Lillian Bay Holdings, LLC; Saint Petersburg, FL; Lyndra Therapeutics, Inc.; Watertown, MA; Pathology AssistTemp, Inc.; Chantilly, VA; PhaseBio Pharmaceuticals, Inc.; Malvern, PA; Quanterix Corporation; Billerica, MA; SomaLogic, Inc.; Boulder, CO; Sorrento Therapeutics, Inc.; Atlanta, GA; Unify R&D; Elkridge, MD and United National Native Council; Payson, AZ have been added as parties to this venture. Also, Space Information Laboratories; Santa Maria, CA, and Valaria Technical Consultants, LLC; Westminster, MD have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MCDC intends to file additional written notifications disclosing all changes in membership. On November 13, 2015, MCDC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on January 6, 2016 (81 FR 513). The last notification was filed with the Department on July 30, 2020. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on August 28, 2020 (85 FR 53401). Suzanne Morris, Chief, Premerger and Division Statistics, Antitrust Division. [FR Doc. 2020–25693 Filed 11–19–20; 8:45 am] BILLING CODE 4410–11–P DEPARTMENT OF JUSTICE Federal Bureau of Investigation [OMB Number 1110–0053] Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension, Without Change, of a Currently Approved Collection; FBI eFOIA Form Federal Bureau of Investigation, Department of Justice. ACTION: 60-Day notice. AGENCY: E:\FR\FM\20NON1.SGM 20NON1

Agencies

[Federal Register Volume 85, Number 225 (Friday, November 20, 2020)]
[Notices]
[Page 74386]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-25693]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant To the National Cooperative Research and 
Production Act of 1993--Medical CBRN Defense Consortium

    Notice is hereby given that, on October 20, 2020, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Medical CBRN Defense 
Consortium (``MCDC'') has filed written notifications simultaneously 
with the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Aardvark Medical, Inc.; Ross, CA; Acer Therapeutics, 
Inc.; Newton, MA; Aegis BioDefense, Inc.; San Carlos, CA; Albany 
Molecular Research Inc. (AMRI); Albany, NY; Arcturus Therapeutics; San 
Diego, CA; ARMSTEL, Inc.; Plano, TX; C2Sense, Inc.; Watertown, MA; 
Captura Biopharma, Inc.; Little Rock, AR; Concord Medical Technology 
Corporation; Grand Forks, ND; Efiia Consulting, LLC; Falls Church, VA; 
Equillium, Inc.; La Jolla, CA; EUSA Pharma (US), LLC; Burlington, MA; 
EWI; Columbus, OH; GenScript USA, Inc.; Piscataway, NJ; Kleo 
Pharmaceuticals; New Haven, CT; Lillian Bay Holdings, LLC; Saint 
Petersburg, FL; Lyndra Therapeutics, Inc.; Watertown, MA; Pathology 
Assist-Temp, Inc.; Chantilly, VA; PhaseBio Pharmaceuticals, Inc.; 
Malvern, PA; Quanterix Corporation; Billerica, MA; SomaLogic, Inc.; 
Boulder, CO; Sorrento Therapeutics, Inc.; Atlanta, GA; Unify R&D; 
Elkridge, MD and United National Native Council; Payson, AZ have been 
added as parties to this venture.
    Also, Space Information Laboratories; Santa Maria, CA, and Valaria 
Technical Consultants, LLC; Westminster, MD have withdrawn as parties 
to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and MCDC intends to file additional 
written notifications disclosing all changes in membership.
    On November 13, 2015, MCDC filed its original notification pursuant 
to Section 6(a) of the Act. The Department of Justice published a 
notice in the Federal Register pursuant to Section 6(b) of the Act on 
January 6, 2016 (81 FR 513).
    The last notification was filed with the Department on July 30, 
2020. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on August 28, 2020 (85 FR 53401).

Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2020-25693 Filed 11-19-20; 8:45 am]
BILLING CODE 4410-11-P